MOLOGEN AG sets course for sustainable success

At its annual general meeting of June 1, 2007, the Berlin-based biotech company MOLOGEN AG has announced far reaching strategic decisions.

Prof. Wittig announced to leave the Board of Directors at the end of this year when his contract expires, to attend to intensified research activities. Prof. Wittig will join the newly founded Scientific Advisory Board of MOLOGEN and thus keep a close connection to the company.

It is planned that Dr. Matthias Schroff, member of the Board of Directors for two years, will take over the position of the CEO. Dr. Schroff is a biochemist and co-inventor of important patents. Before MOLOGEN was founded in 1998 he already had worked for five years as a scientist at the chair of Prof. Wittig.

Scientific Advisory Board founded

Subsequent to the annual shareholders’ meeting the Supervisory Board and the Board of Directors have founded the Scientific Advisory Board. This board shall consist of experts in the field of oncology, clinical development and regulatory affairs and will advise the Executive Board of MOLOGEN on matters of strategic orientation and development of new products. The expertise of the new advisory board will help MOLOGEN to accelerate and optimize the future clinical development procedures.

Prof. Dr. Hans Lutz, up to now member of the Supervisory Board was appointed the first member of the Advisory Board. Prof. Lutz is Vice Dean Planning and New Resources and Head of the Unit of Laboratory Diagnostics at Vetsuisse Faculty at University Zurich.

Increased Focus on clinical development

MOLOGEN’s activities are focused on the development of two products: the dSLIM based pharmaceutical against Colorectal Cancer and the cell based gene therapy against Renal Cell Carcinoma. The preclinical tests of both product candidates are nearly finished. At the moment MOLOGEN prepares clinical studies, which are essential for the approval procedure and which are scheduled to start this year. Hence MOLOGEN will focus on clinical development of the two cancer therapies in the next years. For this purpose MOLOGEN can utilize additional financial and personnel capacities, which were gained by selling the Spanish subsidiary Vivotecnia Research S.L.

To be able to fill the product pipeline of MOLOGEN in the future as well, MOLOGEN plans to intensify the research cooperation with the chair of Prof. Dr. Wittig. Prof. Dr. Wittig is university professor for Molecular Biology and Bioinformatics at Charité Berlin.

Changes in the Supervisory Board

The annual general meeting, which represented more than 50% of the share capital, decided a change in the Supervisory Board: Prof. Dr. Hans Lutz will leave this board and will be replaced by Ferdinand Graf von Thun und Hohenstein, manager of SALVATOR Asset Management GmbH. SALVATOR holds approx. 10% of the shares of MOLOGEN AG presently.

About MOLOGEN

MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview